Русские видео

Сейчас в тренде

Иностранные видео




Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



Update on GAIA trial

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses the GAIA trial (NCT02950051), in which physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) who did not have a TP53 or Del(17p) mutation, were assigned to one of four treatment arms – standard chemoimmunotherapy (FCR or BR), venetoclax plus rituximab, venetoclax plus obinutuzumab, or obinutuzumab plus venetoclax plus inbrutinib. The primary endpoints were minimal residual disease (MRD) negativity rate in peripheral blood and progression-free survival (PFS). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Comments